Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Micvotabart Pelidotin · PYX-201

Antibody-drug conjugate · Cytotoxic, directed at fibronectin EDB splice variant (EDB-FN) (FN1) · developed by Pyxis Oncology

Phase 1/2 Most advanced trial
PYXS Developer
1 Registered trials

What is Micvotabart Pelidotin?

Micvotabart pelidotin is an antibody-drug conjugate that pairs a fully human IgG1 antibody against the extra domain B splice variant of fibronectin with the cytotoxic auristatin derivative Aur0101 via a cleavable linker. The antibody binds EDB-FN in the tumor stroma, releasing the payload, which inhibits microtubule polymerization and kills nearby tumor cells, fibroblasts and tumor vasculature. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PYX-201
Drug type
Antibody-drug conjugate
Targets
fibronectin EDB splice variant (EDB-FN) (FN1), tubulin (secondary target)
Mechanism
Cytotoxic, directed at fibronectin EDB splice variant (EDB-FN) (FN1)
Pathways
microtubule polymerization inhibition, G2/M phase arrest, apoptosis, dendritic cell maturation
Therapy area
Oncology
Developer
Pyxis Oncology, Inc (PYXS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
CEJ2UDF7TX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06795412 Phase 1/2 Advanced Solid Tumors Recruiting PYXS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumors

More from Pyxis Oncology

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PYXS page.

Follow PYXS, the company behind Micvotabart Pelidotin

See PYXS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PYXS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.